GT Biopharma (GTBP) Competitors $1.33 -0.16 (-10.44%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. MIRA, NAII, CVKD, LSTA, RLYB, CING, ELEV, AYTU, BCAB, and ADAPShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Rallybio (RLYB), Cingulate (CING), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors MIRA Pharmaceuticals Natural Alternatives International Cadrenal Therapeutics Lisata Therapeutics Rallybio Cingulate Elevation Oncology Aytu BioPharma BioAtla Adaptimmune Therapeutics GT Biopharma (NASDAQ:GTBP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do analysts recommend GTBP or MIRA? GT Biopharma currently has a consensus price target of $11.00, suggesting a potential upside of 727.07%. MIRA Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 1,097.18%. Given MIRA Pharmaceuticals' higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than GT Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has preferable valuation & earnings, GTBP or MIRA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$4.07-0.33MIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.90 Which has more risk and volatility, GTBP or MIRA? GT Biopharma has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Is GTBP or MIRA more profitable? MIRA Pharmaceuticals' return on equity of -329.63% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,033.08% -228.43% MIRA Pharmaceuticals N/A -329.63%-271.22% Does the media refer more to GTBP or MIRA? In the previous week, MIRA Pharmaceuticals had 4 more articles in the media than GT Biopharma. MarketBeat recorded 6 mentions for MIRA Pharmaceuticals and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.00 beat MIRA Pharmaceuticals' score of 0.91 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MIRA Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in GTBP or MIRA? 8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 3.4% of GT Biopharma shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMIRA Pharmaceuticals beats GT Biopharma on 8 of the 11 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-0.3320.4830.7825.12Price / SalesN/A355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book-1.779.549.375.95Net Income-$13.16M-$54.74M$3.26B$265.46M7 Day Performance-23.97%2.39%1.88%0.96%1 Month Performance-35.44%4.60%3.73%2.47%1 Year Performance-40.76%9.17%28.93%20.24% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.6124 of 5 stars$1.33-10.4%$11.00+727.1%-34.0%$4.35MN/A-0.338Positive NewsEarnings ReportMIRAMIRA Pharmaceuticals3.2669 of 5 stars$1.42+2.9%$17.00+1,097.2%-23.3%$23.35MN/A-2.782News CoverageEarnings ReportShort Interest ↓Gap UpNAIINatural Alternatives International1.3497 of 5 stars$3.70-0.1%N/A-28.0%$22.89M$113.80M-2.66290Positive NewsHigh Trading VolumeCVKDCadrenal Therapeutics2.9322 of 5 stars$10.94-1.9%$32.00+192.5%N/A$22.82MN/A-1.184Short Interest ↑LSTALisata Therapeutics2.6629 of 5 stars$2.77+6.5%$23.50+748.4%-11.9%$22.76M$1M-1.2430Short Interest ↑Gap DownRLYBRallybio2.8085 of 5 stars$0.50-6.4%$10.00+1,912.1%-43.2%$22.19M$640K-0.5340Short Interest ↓CINGCingulate2.6792 of 5 stars$4.05-2.9%$26.00+542.0%-76.5%$21.95MN/A-0.4820News CoverageEarnings ReportShort Interest ↑ELEVElevation Oncology1.3694 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540News CoverageAYTUAytu BioPharma3.6501 of 5 stars$2.24-5.5%$10.00+346.4%-16.7%$21.27M$81M-3.11160Positive NewsBCABBioAtla2.3112 of 5 stars$0.36+2.8%$5.00+1,279.3%-79.5%$20.60M$11M-0.3360ADAPAdaptimmune Therapeutics1.8896 of 5 stars$0.09+10.7%$1.35+1,475.4%-93.5%$20.54M$178.03M-0.32490News CoverageEarnings ReportShort Interest ↑Analyst RevisionGap Down Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Natural Alternatives International Alternatives Cadrenal Therapeutics Alternatives Lisata Therapeutics Alternatives Rallybio Alternatives Cingulate Alternatives Elevation Oncology Alternatives Aytu BioPharma Alternatives BioAtla Alternatives Adaptimmune Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access